6 Cedarbrook Drive, Cranbury, NJ 08512, USA cfpc.jstar@jstar-research.com

Category : PCS2022

Dr. Simon Bates, Rigaku Americas Corp

Dr. Simon Bates is currently V.P. of Science and Technology at Rigaku Americas Corp., where he nurtures collaborative relationships between industry partners and academia in the discovery of new...

Dr. Bob Docherty, Pfizer

Dr. Robert Docherty did his degree and PhD. at Strathclyde University and joined ICI/Zeneca in 1988 where he worked on the solid-state structure and crystallization of dyes, pigments, biocides,...

Digitally Enabled Workflows: Accelerating the Molecule to Medicine Journey

By Dr. Bob Docherty, Pfizer The focus would be on solid form screen & selection, crystallization process development, pre-formulation evaluations, particle engineering and projecting the API attributes to drug...

Dr. Ahmad Sheikh, AbbVie

Dr. Ahmad Sheikh, Head of Solid State & Comp.Chem., AbbVie Ahmad Sheikh is Senior Research Fellow and Head of Solid-State Chemistry at AbbVie. He has over 20 years of...

Reducing or Managing Complexity- New realities with emerging chemical space for small molecule developability

By Dr. Ahmad Sheikh, AbbVie While new chemical entities represent majority of the drugs approved in the last five years, the diversity and complexity of these molecules continue to...

Control, is it achievable in amorphous or poorly crystalline peptide isolations?

By Dr. Jeremy M. Merritt, Eli Lilly and Co. Abstract: pending

Dr. Jeremy M. Merritt, Eli Lilly and Co.

Dr. Jeremy M. Merritt is a Director at Eli Lilly and Co. in the small molecule design and development organization (SMDD).  He currently leads the Particle Design Lab (PDL)...

RSS
Follow by Email
LinkedIn
Share